Search Results

Neuronetics, Inc. today announced that the management team will present at the William Blair 44th Annual Growth Stock Conference on Thursday, June 6, 2024.

Neuronetics, Inc. a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the best neurohealth therapies in the world, announced its financial and operating results for the first quarter of 2024.

Neuronetics, Inc. announced the granting of inducement awards of Restricted Stock Units representing a total of 55,650 shares of the Company’s common stock to thirteen new non-executive employees.

Neuronetics, Inc. announced an expanded commercial partnership with Transformations Care Network, one of the nation’s largest mental health care providers.

Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced that it plans to release first quarter 2024 financial and operating results prior to market open on Tuesday, May 7th, 2024.

Neuronetics, Inc. announced the granting of inducement awards of Restricted Stock Units representing a total of 135,000 shares of the Company’s common stock to eleven new non-executive employees.

Neuronetics, Inc. announced that it plans to release fourth quarter 2023 financial and operating results prior to market open on Tuesday, March 5th, 2024.

Neuronetics, Inc. today announced certain preliminary unaudited fourth quarter and full year 2023 results.